Last reviewed · How we verify
CSL Influenza Vaccine
CSL Influenza Vaccine is a inactivated influenza vaccine Biologic drug developed by Seqirus. It is currently FDA-approved for Seasonal influenza prevention in adults and children. Also known as: Enzira® vaccine, Afluria® vaccine.
This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
This inactivated influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | CSL Influenza Vaccine |
|---|---|
| Also known as | Enzira® vaccine, Afluria® vaccine |
| Sponsor | Seqirus |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated influenza virus antigens (typically from three or four circulating strains) that trigger both humoral and cell-mediated immune responses. Upon vaccination, B cells produce strain-specific antibodies that neutralize viral particles, while T cells develop memory responses to provide broader protection. This priming of the adaptive immune system reduces infection risk and severity if exposure to wild-type influenza occurs.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations (PHASE2)
- A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers (PHASE4)
- Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years (PHASE4)
- A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine (PHASE4)
- A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults (PHASE4)
- A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above. (PHASE3)
- Phase II Study of Pandemic Influenza Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSL Influenza Vaccine CI brief — competitive landscape report
- CSL Influenza Vaccine updates RSS · CI watch RSS
- Seqirus portfolio CI
Frequently asked questions about CSL Influenza Vaccine
What is CSL Influenza Vaccine?
How does CSL Influenza Vaccine work?
What is CSL Influenza Vaccine used for?
Who makes CSL Influenza Vaccine?
Is CSL Influenza Vaccine also known as anything else?
What drug class is CSL Influenza Vaccine in?
What development phase is CSL Influenza Vaccine in?
What are the side effects of CSL Influenza Vaccine?
Related
- Drug class: All inactivated influenza vaccine drugs
- Manufacturer: Seqirus — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Seasonal influenza prevention in adults and children
- Also known as: Enzira® vaccine, Afluria® vaccine
- Compare: CSL Influenza Vaccine vs similar drugs
- Pricing: CSL Influenza Vaccine cost, discount & access